April 28, 2017
Transparency is a relatively new concept to the world of health and health care, considering that just a few short decades ago we were still in the throes of a “doctor-knows-best” model. Today, however, transparency is found on almost every short list of solutions to a variety of health policy problems, ranging from conflicts of interest to rising drug costs to promoting efficient use of health care resources, and more. Doctors are now expected to be transparent about patient diagnoses and treatment options, hospitals are expected to be transparent about error rates, insurers about policy limitations, companies about prices, researchers about data, and policymakers about priorities and rationales for health policy intervention. But a number of important legal and ethical questions remain. For example, what exactly does transparency mean in the context of health, who has a responsibility to be transparent and to whom, what legal mechanisms are there to promote transparency, and what legal protections are needed for things like privacy, intellectual property, and the like? More specifically, when can transparency improve health and health care, and when is it likely to be nothing more than platitude?
This conference aimed to: (1) identify the various thematic roles transparency has been called on to play in American health policy, and why it has emerged in these spaces; (2) understand when, where, how, and why transparency may be a useful policy tool in relation to health and health care, what it can realistically be expected to achieve, and when it is unlikely to be successful, including limits on how patients and consumers utilize information even when we have transparency; (3) assess the legal and ethical issues raised by transparency in health and health care, including obstacles and opportunities; (4) learn from comparative examples of transparency, both in other sectors and outside the United States. In sum, we hope to reach better understandings of this health policy buzzword so that transparency can be utilized as a solution to pressing health policy issues where appropriate, while recognizing its true limitations.
Learn more on our website: http://petrieflom.law.harvard.edu/events/details/2017-annual-conference
The #1 Way to Significantly Cut Employer Pharmacy Benefit Service Costs Witho...TransparentRx
PBMs offer a valuable service, but no one outside the industry truly understands what they do or how they make money. This slide deck puts an end to this now. One can't permanently fix a problem (rising PBM cost) without first knowing how it was created.
The #1 Way to Significantly Cut Employer Pharmacy Benefit Service Costs Witho...TransparentRx
PBMs offer a valuable service, but no one outside the industry truly understands what they do or how they make money. This slide deck puts an end to this now. One can't permanently fix a problem (rising PBM cost) without first knowing how it was created.
This was a lecture in the course "Significant Medical Conditions in Seniors" presented at Peer Learning in Chapel Hill, NC, USA in 2016 by Michael C. Joseph, MD, MPH.
Qui Tam: Off Label Drug Marketing [Data Snapshot]lawsuitlegal
When does the promotion of a pharmaceutical become illegal?
Learn what is considered off-label use for popular drugs and when it becomes unlawful in this data snapshot.
We share the most common types of off-label uses, where it happens most often, and what exceptions provide 'safe haven' protection.
Most doctors and hospitals are prescribing doctors as they should be, with the patients in mind.
However, off-label prescriptions are important when considered in relation to the False Claims Act. The issue of insurance reimbursement takes center stage when drugs are being used unlawfully and these healthcare organizations are receiving insurance payments for improper use.
So take a moment to review the data with us on Off-Label Marketing relating to qui tam actions, today.
Wall Street Mastermind Sector Spotlight - Healthcare (September 2023)SamShiah1
Here are the contents of this month's Healthcare Sector Spotlight:
1. Trading and M&A Comps
2. Obesity Drug Market
3. Illumina/Grail Debacle
4. Royalty Finance
5. J&J Consumer Health IPO
Global Medical Cures™ | Staggering Increase in Generic Drugs PricingGlobal Medical Cures™
Global Medical Cures™ | Staggering Increase in Generic Drugs Pricing
Disclaimer
Global Medical Cures™ does not offer any medical advice, diagnosis, treatment or recommendations. Only your healthcare provider/physician can offer you information and recommendations for you to decide about your healthcare choices.
Eighty percent of Americans believe the prices of prescription medications are unreasonable. PharmacyChecker president and co-founder, Gabriel Levitt, spoke at the New York Retirees Association of District Council 37 September 2018 meeting about the prescription drug price crisis in America and how international online pharmacies can help seniors today. With around 200-300 members in attendance, the members didn’t hold back in expressing shock at the numbers surrounding the current state of drug prices in the United States vs. the rest of the world. Commonly prescribed drugs, that many uninsured or under-insured Americans can’t afford are much less in Canada and other countries.
Wall Street Mastermind Sector Spotlight - Healthcare (October 2023).pdfSamShiah1
Here are the contents of this month's Healthcare Sector Spotlight:
1. Current Market
2. Ozempic Case Study
3. Pharma vs. FTC
4. Healthcare Strikes
5. Sandoz/Novartis Split
6. Amgen Horizon
7. Appendix
Presentación "Análisis de coste efectividad con los nuevos antiagregantes. Causas de infra-utilización en España" del Dr. José Luis Ferreiro durante la Mesa Redonda de Antiagregación de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
BrilliantRxCut.com FREE Discount Card Facts at a Glance FlyerMCM Products, LLC
BrilliantRxDiscount.com by Brilliant Health & Fitness offers a Free Rx Discount card to anyone who wants to save money on their prescription medications. This flyer provides facts at a glance on this amazing card.
Personal protective equipment or PPE has been a major topic of discussion across the nation. The COVID-19 pandemic has exposed major shortages of PPE and health care workers are being asked take care of patients with what some would argue is inadequate protection. The guidelines set by the CDC have changed and recommendations have even gone so far as to approve bandannas as a means for respiratory protection. Some have argued that it is unethical for health care workers to not have adequate protection, while others think it's their duty, protected or not. Adding to this debate has been theft, hoarding and disparate distribution of these critical supplies. During this panel discussion moderator Carmel Shachar, Stephen P. Wood, Christine Mitchell and Dr. Michael Mina explored the ethics of PPE in the COVID-19 pandemic.
March 27, 2020
Each year in low- and middle-income countries thousands of people are detained in hospitals for non-payment of medical bills, despite the fact that such detention is a violation of national and international law. Hospital detention for nonpayment of bills disproportionately affects the most vulnerable people, including post-partum women.
In the US, medical debt manifests itself in other ways, including bankruptcy, litigation to garnish wages, and foregone care. In both contexts, these scandals are the result of failures of financing, priority-setting, and legal oversight.
Without addressing these systemic issues, a "human right to health care" will remain a hollow slogan, as will political promises to achieve universal health coverage.
This event will feature Robert Yates of Chatham House, which has conducted an in-depth investigation of the global phenomenon of hospital detentions. Additional panelists will address manifestations of predatory lending and surprise medical fees in the United States, the ethical imperatives of financing and priority setting for UHC in general, and the implications for thinking about health care as a human right.
For more information, visit our website at: https://petrieflom.law.harvard.edu/events/details/debt-dignity-and-health-care
More Related Content
Similar to Marc Rodwin, "Pharmaceutical Price Transparency and Consumer Choice: An Empirical Test and Conceptual Choice"
This was a lecture in the course "Significant Medical Conditions in Seniors" presented at Peer Learning in Chapel Hill, NC, USA in 2016 by Michael C. Joseph, MD, MPH.
Qui Tam: Off Label Drug Marketing [Data Snapshot]lawsuitlegal
When does the promotion of a pharmaceutical become illegal?
Learn what is considered off-label use for popular drugs and when it becomes unlawful in this data snapshot.
We share the most common types of off-label uses, where it happens most often, and what exceptions provide 'safe haven' protection.
Most doctors and hospitals are prescribing doctors as they should be, with the patients in mind.
However, off-label prescriptions are important when considered in relation to the False Claims Act. The issue of insurance reimbursement takes center stage when drugs are being used unlawfully and these healthcare organizations are receiving insurance payments for improper use.
So take a moment to review the data with us on Off-Label Marketing relating to qui tam actions, today.
Wall Street Mastermind Sector Spotlight - Healthcare (September 2023)SamShiah1
Here are the contents of this month's Healthcare Sector Spotlight:
1. Trading and M&A Comps
2. Obesity Drug Market
3. Illumina/Grail Debacle
4. Royalty Finance
5. J&J Consumer Health IPO
Global Medical Cures™ | Staggering Increase in Generic Drugs PricingGlobal Medical Cures™
Global Medical Cures™ | Staggering Increase in Generic Drugs Pricing
Disclaimer
Global Medical Cures™ does not offer any medical advice, diagnosis, treatment or recommendations. Only your healthcare provider/physician can offer you information and recommendations for you to decide about your healthcare choices.
Eighty percent of Americans believe the prices of prescription medications are unreasonable. PharmacyChecker president and co-founder, Gabriel Levitt, spoke at the New York Retirees Association of District Council 37 September 2018 meeting about the prescription drug price crisis in America and how international online pharmacies can help seniors today. With around 200-300 members in attendance, the members didn’t hold back in expressing shock at the numbers surrounding the current state of drug prices in the United States vs. the rest of the world. Commonly prescribed drugs, that many uninsured or under-insured Americans can’t afford are much less in Canada and other countries.
Wall Street Mastermind Sector Spotlight - Healthcare (October 2023).pdfSamShiah1
Here are the contents of this month's Healthcare Sector Spotlight:
1. Current Market
2. Ozempic Case Study
3. Pharma vs. FTC
4. Healthcare Strikes
5. Sandoz/Novartis Split
6. Amgen Horizon
7. Appendix
Presentación "Análisis de coste efectividad con los nuevos antiagregantes. Causas de infra-utilización en España" del Dr. José Luis Ferreiro durante la Mesa Redonda de Antiagregación de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
BrilliantRxCut.com FREE Discount Card Facts at a Glance FlyerMCM Products, LLC
BrilliantRxDiscount.com by Brilliant Health & Fitness offers a Free Rx Discount card to anyone who wants to save money on their prescription medications. This flyer provides facts at a glance on this amazing card.
Similar to Marc Rodwin, "Pharmaceutical Price Transparency and Consumer Choice: An Empirical Test and Conceptual Choice" (20)
Personal protective equipment or PPE has been a major topic of discussion across the nation. The COVID-19 pandemic has exposed major shortages of PPE and health care workers are being asked take care of patients with what some would argue is inadequate protection. The guidelines set by the CDC have changed and recommendations have even gone so far as to approve bandannas as a means for respiratory protection. Some have argued that it is unethical for health care workers to not have adequate protection, while others think it's their duty, protected or not. Adding to this debate has been theft, hoarding and disparate distribution of these critical supplies. During this panel discussion moderator Carmel Shachar, Stephen P. Wood, Christine Mitchell and Dr. Michael Mina explored the ethics of PPE in the COVID-19 pandemic.
March 27, 2020
Each year in low- and middle-income countries thousands of people are detained in hospitals for non-payment of medical bills, despite the fact that such detention is a violation of national and international law. Hospital detention for nonpayment of bills disproportionately affects the most vulnerable people, including post-partum women.
In the US, medical debt manifests itself in other ways, including bankruptcy, litigation to garnish wages, and foregone care. In both contexts, these scandals are the result of failures of financing, priority-setting, and legal oversight.
Without addressing these systemic issues, a "human right to health care" will remain a hollow slogan, as will political promises to achieve universal health coverage.
This event will feature Robert Yates of Chatham House, which has conducted an in-depth investigation of the global phenomenon of hospital detentions. Additional panelists will address manifestations of predatory lending and surprise medical fees in the United States, the ethical imperatives of financing and priority setting for UHC in general, and the implications for thinking about health care as a human right.
For more information, visit our website at: https://petrieflom.law.harvard.edu/events/details/debt-dignity-and-health-care
March 24, 2020
This event will highlight the challenges and opportunities in harnessing artificial intelligence (AI) technologies to serve the needs of individuals with disabilities and dependencies. AI can improve the lives of people with disabilities, such as smart devices supporting people with physical disabilities or sight loss. On the other hand, AI outputs can also reflect discriminatory biases present in the underlying data used to develop the algorithms. While this “garbage in, garbage out” principle is well documented in respect to AI and gender or race, it is understudied in respect to disability or dependencies.
Interdisciplinary panels of legal scholars, ethicists, AI developers, medical and service providers, and advocates with disabilities/ dependencies will explore best practices and guidelines for stakeholders, guided by ethical principles, legal considerations, and the needs of people with disabilities/ dependencies. Participants will seek to articulate clear criteria for developers and medical providers looking to harness the potential of AI to serve individuals with disabilities/ dependencies, including those whose disabilities/ dependencies are the result of aging, injury, or disease, and the caregivers -- including both professionals and unpaid friends and families -- who support some of these individuals.
This webinar was free and open the public.
For more information, visit our website at https://petrieflom.law.harvard.edu/events/details/artificial-intelligence-and-disability-dependency
March 24, 2020
This event will highlight the challenges and opportunities in harnessing artificial intelligence (AI) technologies to serve the needs of individuals with disabilities and dependencies. AI can improve the lives of people with disabilities, such as smart devices supporting people with physical disabilities or sight loss. On the other hand, AI outputs can also reflect discriminatory biases present in the underlying data used to develop the algorithms. While this “garbage in, garbage out” principle is well documented in respect to AI and gender or race, it is understudied in respect to disability or dependencies.
Interdisciplinary panels of legal scholars, ethicists, AI developers, medical and service providers, and advocates with disabilities/ dependencies will explore best practices and guidelines for stakeholders, guided by ethical principles, legal considerations, and the needs of people with disabilities/ dependencies. Participants will seek to articulate clear criteria for developers and medical providers looking to harness the potential of AI to serve individuals with disabilities/ dependencies, including those whose disabilities/ dependencies are the result of aging, injury, or disease, and the caregivers -- including both professionals and unpaid friends and families -- who support some of these individuals.
This webinar was free and open the public.
For more information, visit our website at https://petrieflom.law.harvard.edu/events/details/artificial-intelligence-and-disability-dependency
February 14, 2020
On February 14, 2020, Harvard Medical School Center for Bioethics and the Program on Regulation, Therapeutics, and Law (PORTAL) at Brigham and Women's Hospital, in collaboration with the Petrie-Flom Center hosted the monthly health policy consortium on sugar-sweetened beverage excise taxes.
In recent years, some cities have tried to impose soda taxes and other new policies to reduce the obesity epidemic in the US—particularly among children—and its critical impact on society and the health care system. How effective are these policies? What is blocking their uptake? What alternatives should we consider?
For more information visit our website at: https://petrieflom.law.harvard.edu/events/details/soda-taxes-and-other-policy-responses-to-the-american-obesity-epidemic
February 14, 2020
On February 14, 2020, Harvard Medical School Center for Bioethics and the Program on Regulation, Therapeutics, and Law (PORTAL) at Brigham and Women's Hospital, in collaboration with the Petrie-Flom Center hosted the monthly health policy consortium on sugar-sweetened beverage excise taxes.
In recent years, some cities have tried to impose soda taxes and other new policies to reduce the obesity epidemic in the US—particularly among children—and its critical impact on society and the health care system. How effective are these policies? What is blocking their uptake? What alternatives should we consider?
For more information visit our website at: https://petrieflom.law.harvard.edu/events/details/soda-taxes-and-other-policy-responses-to-the-american-obesity-epidemic
October 23, 2019
The future of neuroscience and law will be a computational future, as both fields are increasingly integrating artificial intelligence and machine learning. But what will this future look like? Can AI and digital technologies promote justice, diversity, and inclusion? Or will these technologies replicate, or even exacerbate, existing inequalities and biases? In this lunchtime event, leading experts in artificial intelligence, computational psychiatry, and the law discussed these questions as they explored how AI and digital technologies can advance social good through improved social, psychiatric, and legal interventions.
For more information, visit our website at https://petrieflom.law.harvard.edu/events/details/computational-justice
October 7, 2019
On October 7, 2019, the Harvard Global Health Institute will host a one-day symposium to explore what enabled this visionary program, and to showcase how it has transformed not just the worldwide HIV/AIDS response but global health delivery more broadly.
There are many lessons learned in PEPFAR’s story - from what it took to build a supply chain where there was none, to establishing the use of generic antiretroviral therapies (ARTs) and leveraging human capacity. This event convened the early architects of PEPFAR as well as experts and implementers currently leading the charge. We took a historically informed look at what it will take to stop global transmission, and shared tools useful for others hoping to move the needle on vexing problems in global health.
For more information, visit our website at https://petrieflom.law.harvard.edu/events/details/15-years-of-pepfar
October 7, 2019
On October 7, 2019, the Harvard Global Health Institute will host a one-day symposium to explore what enabled this visionary program, and to showcase how it has transformed not just the worldwide HIV/AIDS response but global health delivery more broadly.
There are many lessons learned in PEPFAR’s story - from what it took to build a supply chain where there was none, to establishing the use of generic antiretroviral therapies (ARTs) and leveraging human capacity. This event convened the early architects of PEPFAR as well as experts and implementers currently leading the charge. We took a historically informed look at what it will take to stop global transmission, and shared tools useful for others hoping to move the needle on vexing problems in global health.
For more information, visit our website at https://petrieflom.law.harvard.edu/events/details/15-years-of-pepfar
October 7, 2019
On October 7, 2019, the Harvard Global Health Institute will host a one-day symposium to explore what enabled this visionary program, and to showcase how it has transformed not just the worldwide HIV/AIDS response but global health delivery more broadly.
There are many lessons learned in PEPFAR’s story - from what it took to build a supply chain where there was none, to establishing the use of generic antiretroviral therapies (ARTs) and leveraging human capacity. This event convened the early architects of PEPFAR as well as experts and implementers currently leading the charge. We took a historically informed look at what it will take to stop global transmission, and shared tools useful for others hoping to move the needle on vexing problems in global health.
For more information, visit our website at https://petrieflom.law.harvard.edu/events/details/15-years-of-pepfar
October 7, 2019
On October 7, 2019, the Harvard Global Health Institute will host a one-day symposium to explore what enabled this visionary program, and to showcase how it has transformed not just the worldwide HIV/AIDS response but global health delivery more broadly.
There are many lessons learned in PEPFAR’s story - from what it took to build a supply chain where there was none, to establishing the use of generic antiretroviral therapies (ARTs) and leveraging human capacity. This event convened the early architects of PEPFAR as well as experts and implementers currently leading the charge. We took a historically informed look at what it will take to stop global transmission, and shared tools useful for others hoping to move the needle on vexing problems in global health.
For more information, visit our website at https://petrieflom.law.harvard.edu/events/details/15-years-of-pepfar
October 7, 2019
On October 7, 2019, the Harvard Global Health Institute will host a one-day symposium to explore what enabled this visionary program, and to showcase how it has transformed not just the worldwide HIV/AIDS response but global health delivery more broadly.
There are many lessons learned in PEPFAR’s story - from what it took to build a supply chain where there was none, to establishing the use of generic antiretroviral therapies (ARTs) and leveraging human capacity. This event convened the early architects of PEPFAR as well as experts and implementers currently leading the charge. We took a historically informed look at what it will take to stop global transmission, and shared tools useful for others hoping to move the needle on vexing problems in global health.
For more information, visit our website at https://petrieflom.law.harvard.edu/events/details/15-years-of-pepfar
October 7, 2019
On October 7, 2019, the Harvard Global Health Institute will host a one-day symposium to explore what enabled this visionary program, and to showcase how it has transformed not just the worldwide HIV/AIDS response but global health delivery more broadly.
There are many lessons learned in PEPFAR’s story - from what it took to build a supply chain where there was none, to establishing the use of generic antiretroviral therapies (ARTs) and leveraging human capacity. This event convened the early architects of PEPFAR as well as experts and implementers currently leading the charge. We took a historically informed look at what it will take to stop global transmission, and shared tools useful for others hoping to move the needle on vexing problems in global health.
For more information, visit our website at https://petrieflom.law.harvard.edu/events/details/15-years-of-pepfar
October 7, 2019
On October 7, 2019, the Harvard Global Health Institute will host a one-day symposium to explore what enabled this visionary program, and to showcase how it has transformed not just the worldwide HIV/AIDS response but global health delivery more broadly.
There are many lessons learned in PEPFAR’s story - from what it took to build a supply chain where there was none, to establishing the use of generic antiretroviral therapies (ARTs) and leveraging human capacity. This event convened the early architects of PEPFAR as well as experts and implementers currently leading the charge. We took a historically informed look at what it will take to stop global transmission, and shared tools useful for others hoping to move the needle on vexing problems in global health.
For more information, visit our website at https://petrieflom.law.harvard.edu/events/details/15-years-of-pepfar
September 10, 2019
Book Talk: Birth Rights and Wrongs: How Medicine and Technology are Remaking Reproduction and the Law
Millions of Americans rely on the likes of birth control, IVF, and genetic testing to make plans as intimate and far-reaching as any over a lifetime. This is no less than the medicine of miracles. It fills empty cradles, frees families from terrible disease, and empowers them to fashion their lives on their own terms. But accidents happen.
Pharmacists mix up pills. Lab techs misread tests. Obstetricians tell women their healthy fetuses would be stillborn. Political and economic forces conspire against regulation. And judges throw up their hands when professionals foist parenthood on people who didn't want it, or childlessness on those who did. Failed abortions, switched donors, and lost embryos may be first-world problems. But these aren't innocent lapses or harmless errors. They're wrongs in need of rights.
At this event, author Dov Fox and an expert panel discussed his book Birth Rights and Wrongs: How Medicine and Technology are Remaking Reproduction and the Law (Oxford University Press, 2019). Panelists explored the ways in which the book seeks to lift the curtain on reproductive negligence, give voice to the lives it upends, and vindicate the interests that advances in medicine and technology bring to full expression. They also examined the book's effort to force citizens and courts to rethink the reproductive controversies of our time, and to equip us to meet the new challenges -- from womb transplants to gene editing -- that lie just over the horizon.
Learn more: https://petrieflom.law.harvard.edu/events/details/book-talk-birth-rights-and-wrongs
September 10, 2019
Book Talk: Birth Rights and Wrongs: How Medicine and Technology are Remaking Reproduction and the Law
Millions of Americans rely on the likes of birth control, IVF, and genetic testing to make plans as intimate and far-reaching as any over a lifetime. This is no less than the medicine of miracles. It fills empty cradles, frees families from terrible disease, and empowers them to fashion their lives on their own terms. But accidents happen.
Pharmacists mix up pills. Lab techs misread tests. Obstetricians tell women their healthy fetuses would be stillborn. Political and economic forces conspire against regulation. And judges throw up their hands when professionals foist parenthood on people who didn't want it, or childlessness on those who did. Failed abortions, switched donors, and lost embryos may be first-world problems. But these aren't innocent lapses or harmless errors. They're wrongs in need of rights.
At this event, author Dov Fox and an expert panel discussed his book Birth Rights and Wrongs: How Medicine and Technology are Remaking Reproduction and the Law (Oxford University Press, 2019). Panelists explored the ways in which the book seeks to lift the curtain on reproductive negligence, give voice to the lives it upends, and vindicate the interests that advances in medicine and technology bring to full expression. They also examined the book's effort to force citizens and courts to rethink the reproductive controversies of our time, and to equip us to meet the new challenges -- from womb transplants to gene editing -- that lie just over the horizon.
Learn more: https://petrieflom.law.harvard.edu/events/details/book-talk-birth-rights-and-wrongs
May 17, 2019
Breakthroughs in genetics have often raised complex ethical and legal questions, which loom ever larger as genetic testing is becoming more commonplace, affordable, and comprehensive and genetic editing becomes poised to be a consumer technology. As genetic technologies become more accessible to individuals, the ethical and legal questions around the consumer use of these technologies become more pressing.
As these questions become more pressing, now is the time to re-consider what ethical and regulatory safeguards should be implemented and discuss the many questions raised by advancements in consumer genetics.
Presentation: Vardit Ravitsky, Associate Professor, Bioethics Programs, Department of Social and Preventive Medicine, School of Public Health, University of Montreal; Director, Ethics and Health Branch, Center for Research on Ethics - Prenatal Genome Sequencing: Ethical and Regulatory Implications for Post-Birth Access to Information
Learn more: https://petrieflom.law.harvard.edu/events/details/2019-petrie-flom-center-annual-conference
May 17, 2019
Breakthroughs in genetics have often raised complex ethical and legal questions, which loom ever larger as genetic testing is becoming more commonplace, affordable, and comprehensive and genetic editing becomes poised to be a consumer technology. As genetic technologies become more accessible to individuals, the ethical and legal questions around the consumer use of these technologies become more pressing.
As these questions become more pressing, now is the time to re-consider what ethical and regulatory safeguards should be implemented and discuss the many questions raised by advancements in consumer genetics.
Presentation: Liza Vertinsky, Associate Professor of Law, Emory University School of Law and Emory Global Health Institute Faculty Fellow (with Yaniv Heled) - Genetic Privacy and Public Figures
Learn more: https://petrieflom.law.harvard.edu/events/details/2019-petrie-flom-center-annual-conference
May 17, 2019
Breakthroughs in genetics have often raised complex ethical and legal questions, which loom ever larger as genetic testing is becoming more commonplace, affordable, and comprehensive and genetic editing becomes poised to be a consumer technology. As genetic technologies become more accessible to individuals, the ethical and legal questions around the consumer use of these technologies become more pressing.
As these questions become more pressing, now is the time to re-consider what ethical and regulatory safeguards should be implemented and discuss the many questions raised by advancements in consumer genetics.
Presentation: Scott Schweikart, Senior Research Associate, Council on Ethical and Judicial Affairs, American Medical Association and Legal Editor, AMA Journal of Ethics - Human Gene Editing: An Ethical Analysis and Arguments for Regulatory Guidance at Both the National and Global Levels
Learn more: https://petrieflom.law.harvard.edu/events/details/2019-petrie-flom-center-annual-conference
May 17, 2019
Breakthroughs in genetics have often raised complex ethical and legal questions, which loom ever larger as genetic testing is becoming more commonplace, affordable, and comprehensive and genetic editing becomes poised to be a consumer technology. As genetic technologies become more accessible to individuals, the ethical and legal questions around the consumer use of these technologies become more pressing.
As these questions become more pressing, now is the time to re-consider what ethical and regulatory safeguards should be implemented and discuss the many questions raised by advancements in consumer genetics.
Presentation: Emily Qian, Genetic Counselor, Veritas Genetics (with Magalie Leduc, Rebecca Hodges, Bryan Cosca, Ryan Durigan, Laurie McCright, Doug Flood, and Birgit Funke) - Physician-Mediated Elective Whole Genome Sequencing Tests: Impacts on Informed Consent
Learn more: https://petrieflom.law.harvard.edu/events/details/2019-petrie-flom-center-annual-conference
More from The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics (20)
INFECTION OF THE BRAIN -ENCEPHALITIS ( PPT)blessyjannu21
Neurological system includes brain and spinal cord. It plays an important role in functioning of our body. Encephalitis is the inflammation of the brain. Causes include viral infections, infections from insect bites or an autoimmune reaction that affects the brain. It can be life-threatening or cause long-term complications. Treatment varies, but most people require hospitalization so they can receive intensive treatment, including life support.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Veterinary Diagnostics Market PPT 2024: Size, Growth, Demand and Forecast til...IMARC Group
The global veterinary diagnostics market size reached US$ 6.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.6 Billion by 2032, exhibiting a growth rate (CAGR) of 7.3% during 2024-2032.
More Info:- https://www.imarcgroup.com/veterinary-diagnostics-market
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac CareDr. David Greene Arizona
Explore the groundbreaking work of Dr. David Greene, a pioneer in regenerative medicine, who is revolutionizing the field of cardiology through stem cell therapy in Arizona. This ppt delves into how Dr. Greene's innovative approach is providing non-surgical, effective treatments for heart disease, using the body's own cells to repair heart damage and improve patient outcomes. Learn about the science behind stem cell therapy, its benefits over traditional cardiac surgeries, and the promising future it holds for modern medicine. Join us as we uncover how Dr. Greene's commitment to stem cell research and therapy is setting new standards in healthcare and offering new hope to cardiac patients.
This document is designed as an introductory to medical students,nursing students,midwives or other healthcare trainees to improve their understanding about how health system in Sri Lanka cares children health.
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
About this webinar: This talk will introduce what cancer rehabilitation is, where it fits into the cancer trajectory, and who can benefit from it. In addition, the current landscape of cancer rehabilitation in Canada will be discussed and the need for advocacy to increase access to this essential component of cancer care.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
COVID-19 PCR tests remain a critical component of safe and responsible travel in 2024. They ensure compliance with international travel regulations, help detect and control the spread of new variants, protect vulnerable populations, and provide peace of mind. As we continue to navigate the complexities of global travel during the pandemic, PCR testing stands as a key measure to keep everyone safe and healthy. Whether you are planning a business trip, a family vacation, or an international adventure, incorporating PCR testing into your travel plans is a prudent and necessary step. Visit us at https://www.globaltravelclinics.com/
PET CT beginners Guide covers some of the underrepresented topics in PET CTMiadAlsulami
This lecture briefly covers some of the underrepresented topics in Molecular imaging with cases , such as:
- Primary pleural tumors and pleural metastases.
- Distinguishing between MPM and Talc Pleurodesis.
- Urological tumors.
- The role of FDG PET in NET.
Trauma Outpatient Center is a comprehensive facility dedicated to addressing mental health challenges and providing medication-assisted treatment. We offer a diverse range of services aimed at assisting individuals in overcoming addiction, mental health disorders, and related obstacles. Our team consists of seasoned professionals who are both experienced and compassionate, committed to delivering the highest standard of care to our clients. By utilizing evidence-based treatment methods, we strive to help our clients achieve their goals and lead healthier, more fulfilling lives.
Our mission is to provide a safe and supportive environment where our clients can receive the highest quality of care. We are dedicated to assisting our clients in reaching their objectives and improving their overall well-being. We prioritize our clients' needs and individualize treatment plans to ensure they receive tailored care. Our approach is rooted in evidence-based practices proven effective in treating addiction and mental health disorders.
International Cancer Survivors Day is celebrated during June, placing the spotlight not only on cancer survivors, but also their caregivers.
CANSA has compiled a list of tips and guidelines of support:
https://cansa.org.za/who-cares-for-cancer-patients-caregivers/
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
Marc Rodwin, "Pharmaceutical Price Transparency and Consumer Choice: An Empirical Test and Conceptual Choice"
1. CAN TRANSPARENCY REDUCE
RETAIL PHARMACEUTICAL PRICE DISPARITIES
OR LOWER COSTS FOR CONSUMERS?
Marc A Rodwin, J.D., Ph.D.
Suffolk University Law School
Transparency in Health and Health Care:
Legal and Ethical Possibilities and Limits
2017 Harvard Law School Petrie-Flom Center
April 28, 2017
2.
3.
4. 3 commonly asserted propositions re Rx transparency
1) Prescription drug prices lack transparency.
2) Lack of price transparency is new and contributes to wide
price variations.
3) Increasing transparency is sufficient to reduce price
variation and lower prices.
5. Better supported alternative propositions
1) There was little pharmaceutical price transparency in the
1960s due to restrictions on advertising and the lack of
technology to facilitate learning prices. These obstacles
have since been removed.
1) Variation in retail prescription drug prices in the U.S. has
existed since the mid-1960s and persists despite recent
increased price transparency.
1) Other factors explain wide prices variation and high prices:
6. Other factors explain wide prices variation and high prices:
a) Retailers, Pharmaceutical Benefit Managers (PBMs) and
manufacturers price discriminate to increase revenue.
b) Insurance copayment policies result in some consumers
paying more than others for identical medications.
c) High transaction costs deter consumers from comparing
prices effectively or purchasing medication based on price.
d) Wide price variation is due to retailers, PBM and
manufacturers marketing strategies and the absence of perfect
competition.
7. 1967. Hastings, Glen E., and Richard Kunnes. "Predicting prescription prices." New England Journal
of Medicine 277, no. 12 (1967): 625-628.
1970. What is the price of an Rx Drug? Consumer Reports 35 no. 5 279 (May 1970)
1973. Wertheimer, Albert I. "Pricing pharmaceutical service—art, science or whim." Journal of the
American Pharmaceutical Association 13, no. 1 (1973): 11-12, at 11.
1975. Cady, John F., and Alan R. Andreasen. "Price levels, price practices and price discrimination in a
retail market for prescription drugs." The Journal of Consumer Affairs (1975): 33-48.
1977. Berki, S. E., J. W. Richard, and H. A. Weeks. "The mysteries of prescription pricing in retail
pharmacies." Medical care 15, no. 3 (1977): 241-250.
Wertheimer, Albert I. "Pricing pharmaceutical service—art, science or whim." Journal of the American
Pharmaceutical Association 13, no. 1 (1973): 11-12, at 11.
1986. Bloom, Bernard S., David J. Wierz, and Mark V. Pauly. "Cost and price of comparable branded
and generic pharmaceuticals." JAMA 256, no. 18 (1986): 2523-2530.
8. Uninsured
1) Low cost generics sold at for $4 to $10 for
a 30 day supply.
• Low cost list varies with pharmacy.
2) Other generics branded drugs sold at many
prices by each pharmacy.
• In Boston 6 chains, 1 mail order retailer;
many independent. Pharmacies.
A) List price;
B) Membership discount;
C) Discounts through phone apps vary with
pharmacy and phone app.
• Good RX
• Well Rx
• Rx Price Quotes
• Easy Drug
3) Pet med web sites sell human drugs
sometimes at lower price than pharmacies.
Insured
1)Co-payments vary with market segment and
insurer.
2) Copayments vary with which of 3 to 5
copayment tiers the drug is placed.
3) Purchasing drug without insurance from
low-price drug list or with discount coupon is
sometimes less expensive paying the insurance
copayment.
4) Pet med web sites sometimes charge lower
prices than standard pharmacies.
13. PHARMACY Lowest $ amount between
highest and lowest price
for a single medication
Highest $ amount between
highest and lowest price for
a single medication
$ amount
between lowest
and highest price
difference
Mean savings
when
purchasing at
lowest price*
Health Warehouse $0
(Aripiprazole Digoxin,
Erythromycin, Piroxicam,
Risperidone. No price
difference
$14.12
(Doxycycline)
$14.12 $3.47
Costco $1.85
(Metformin)
$590.11
(Aripiprazole)
$588.26 $150.98
CVS $12.11
(Metformin)
$731.18
(Aripiprazole)
$719.07 $172.18
Rite Aid $6.03
(Metformin)
$507.06
(Aripiprazole)
$501.03 $145.11
Walgreens $10.07
(Metformin)
$674.93
(Aripiprazole)
$664.86 $149.64
Walmart $10.92
(Methazolamide)
$232.70
(Olanzapine)
$221.78 $91.58
Table 6: Range of prices offered within a single pharmacy:
Lowest $ difference between high and low price; highest $ difference between high and low price; Mean
saving by purchasing drug at lowest price.
26. Transparency and Retail Rx Drug Price Variation
1) Tools that can reveal price information are often used
to facilitate price discrimination. Phone apps facilitate
comparing prices of competing retailers but sellers often
use them to market drugs and offer different price
discounts to various consumers.
2) Retail price variations are due price discrimination,
marketing strategies and differences in insurance
copayments rather than lack of price transparency.
27. 3) The promotion of price transparency is often necessary
but insufficient to reduce retail price variation and anti-
competitive practices.
4) Reducing the cost of obtaining price information could
help lower prices for consumers if drugs were sold
through a regulated exchange. Many proponents of
transparency dislike regulation and will oppose a
regulated exchange even though it would produce optimal
price transparency.